ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
Marc Kennis, May 1, 2023
ASX Life Sciences stocks are back, baby!
ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.
The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.
He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).
Stuart Roberts on AusBiz talking ASX Life Sciences stocks
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Electro Optic Systems (ASX:EOS) US$42m Slinger Order Lands as Defence Demand Heats Up
New Highs, New Contract, But Valuation Is Now the Debate Electro Optic Systems has pushed to new highs on the…
Sovereign Metals (ASX:SVM) Japan Wants Kasiya Rutile, 70,000 tpa Targeted
Kasiya gets a handshake from a Tier One Trading Partner Sovereign Metals surged 10% today after signing a memorandum of…
Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?
After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear,…